Really, Abbott is bearing the brunt of this.

They have painted themselves into a corner. They have articulated a position and set a price that is well below $72, so it is going to be tough.

I think that there was an element of tiredness with all the recalls.

The lion’s share of what will be divested is going to Abbott.

I just don’t think this is over yet. Boston really feels this is a redefining move for them.

I don’t think this is over yet.

It’s going to be a test of wills.

At the end of the day, Boston is going to run out of cash ahead of J&J. Boston’s really going to have to go for broke.

Guidant stock is really going to be driven solely by the perception of whether the news is bad enough not to buy it. You’ve got people getting worried that Boston may get cold feet. That’s...

J&J is flexing its muscles. That’s why J&J has come back so aggressively.

I would not be surprised to see J&J come back. They’ve got $16 billion in cash at the end of 2005. They have tremendous financial resources. It’s up to them.